Narayana Hrudayalaya Ltd.
Narayana Hrudayalaya Ltd. operates in Hospital, part of the Healthcare sector. It booked ₹2,844 cr of revenue in its latest quarter (Q2 FY27) and kept 10.6% of sales as profit. It is the 5th largest of 9 Hospital companies we track, by market value.
| Segment | FY25 | FY26 | Share |
|---|---|---|---|
| Medical and healthcare related services | 5,609 | 7,689 | 99% → 95% |
| Others | 31 | 386 | 1% → 5% |
| Total | 5,640 | 8,074 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 59% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 80–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 65
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in NH?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹2,844 cr |
| Other Income | ₹52 cr |
| Total Income | ₹2,896 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹554 cr |
| Inventory Change (±) | ₹-7 cr |
| Employee Benefit Expense | ₹736 cr |
| Finance Costs | ₹97 cr |
| Depreciation & Amortisation | ₹163 cr |
| Other Expenses | ₹1,007 cr |
| Total Expenses | ₹2,550 cr |
| Exceptional Items | ₹-2 cr |
| Profit before Tax | ₹343 cr |
| Tax Expense | ₹42 cr |
| Net Profit | ₹301 cr |
| Net margin on total income | 10.4% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 2,594 cr | 2,684 cr | 2,844 cr |
| Total income | 2,623 cr | 2,719 cr | 2,896 cr |
| Expenses | 2,329 cr | 2,457 cr | 2,550 cr |
| Profit before tax | 294 cr | 262 cr | 343 cr |
| Tax | 64 cr | 53 cr | 42 cr |
| Net profit (owners' share) | 224 cr | 207 cr | 301 cr |
| Net margin (owners' share, on revenue) | 8.6% | 7.7% | 10.6% |
| EPS (₹) | 11.22 | 10.20 | 14.82 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹8,440 | ₹1.21 L cr | 52.2 | 24.5% | 8.2% | — |
| Max Healthcare Institute Limited | ₹896 | ₹87,160 cr | 52.6 | 14.6% | 16.2% | — |
| Manipal Health Enterprises Limited | ₹642 | ₹75,740 cr | 81.9 | — | 7.5% | — |
| Fortis Healthcare Limited | ₹786 | ₹59,306 cr | 55.6 | 10.8% | 10.5% | — |
| Narayana Hrudayalaya Ltd.this company | ₹1,871 | ₹38,228 cr | 31.6 | 24.1% | 10.6% | — |
| Global Health Limited | ₹1,326 | ₹35,621 cr | 40.4 | 20.3% | 14.9% | — |
| Aster DM Quality Care Limited | ₹681 | ₹35,303 cr | 549.5 | 1.4% | 1.2% | — |
| Krishna Institute of Medical Sciences Limited | ₹731 | ₹30,681 cr | 175.6 | 7.4% | 3.5% | — |
| Dr. Agarwal's Health Care Limited | ₹513 | ₹16,256 cr | 89.7 | 8.9% | 7.4% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹4.5 / share | 17 Jul 2026 |
| Dividend | ₹4.5 / share | 1 Aug 2025 |
| Dividend | ₹4 / share | 2 Aug 2024 |
| Dividend | ₹2.5 / share | 7 Jul 2023 |
| Dividend | ₹1 / share | 22 Aug 2022 |
| Dividend | ₹1 / share | 11 Mar 2020 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 10 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.